arrow
M

Melissa L. Johnson

Sarah Cannon Research Institute
H指数:65
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer

TROP2的归一化膜比作为datopotamab deruxtecan在非小细胞肺癌中预测临床结局的指标

2026-11-110
OAAI
SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation

SKYSCRAPER-03研究:比较替拉戈鲁单抗联合阿替利珠单抗与度伐利尤单抗治疗局部晚期、不可切除的III期非小细胞肺癌(接受铂类为基础的同步化放疗后)的III期研究

2026-08-060
PRE
Phase 1/2 study of INCAGN01876, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, plus immunotherapy for advanced cancers

INCAGN01876(一种抗糖皮质激素诱导的肿瘤坏死因子受体激动剂单克隆抗体)联合免疫疗法治疗晚期癌症的Ⅰ/Ⅱ期研究

2026-07-300
OAAI
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer

AZD2811在复发/难治性小细胞肺癌的I期剂量扩展研究中通过生物标志物分析进行疗效监测

2026-04-030
OAAI
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial

Ifinatamab deruxtecan,一种B7-H3靶向抗体—药物偶联物,在晚期实体瘤患者中的研究(IDeate-PanTumor01):一项1/2期试验的剂量递增结果

2026-03-300
PRE
Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1–high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part 1

度瓦尼单抗联合齐木利单抗作为PD-L1高表达、晚期非小细胞肺癌患者的一线治疗:来自随机II期ARC-10研究的结果,第一部分

2026-02-110
OAAI
MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors

MDX-2001-101研究方案:一项评估MDX2001单药治疗在晚期实体瘤患者中的I/IIa期、多中心、首次人体、开放标签临床试验

2026-01-010
OA
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast

II期COPERNICUS研究:皮下注射Amivantamab联合Lazertinib作为一线治疗,或与化疗联合作为二线治疗,用于EGFR突变非小细胞肺癌的播客视频

2025-10-110
OA
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC—A Brief Report

更新了来自II期PHAROS研究的encorafenib联合binimetinib在BRAF V600E突变型转移性NSCLC患者中的疗效和安全性——简报

2025-06-040
OAAI
A novel approach for first-in-human dose selection using population dose-response modelling to find a minimum anticipated biological effect level

一种利用群体剂量-反应模型确定最小预期生物效应水平,以进行首次人体试验剂量选择的新方法

2025-04-270
PRE
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies

I期IMCnyeso研究,该研究是一种靶向NY-ESO-1表达性恶性病变的T细胞受体双特异性ImmTAC。

2025-04-010
OAAI
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary
2025-03-010
OAAI
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial

先前接受过Tarlatamab治疗的小细胞肺癌患者的患者报告结局: DeLLphi-301 2期试验的结果

2025-03-010
OAAI
Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)( vol 197 , 107960 , 2024)

真实世界中索托拉西比相较于多西他赛在二线及二线以上治疗中晚期非小细胞肺癌(NSCLC)患者的比较疗效(vol 197, 107960, 2024)

2025-02-010
OAAI
First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain-Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
2024-12-310
OAAI